NASDAQ$CELC
Celcuity Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2020 and summarized recent business progress.
Celcuity Inc. reported a net loss of $2.20 million, or $0.21 per share, for the second quarter of 2020. The company's cash and cash equivalents were $15.4 million as of June 30, 2020, which is expected to support operations through 2021.
- Presented data for first CELsignia Pathway Activity Test for ovarian cancer at AACR Annual Meeting
- Expect to announce new clinical trial collaborations with pharmaceutical companies and trial sponsors by the end of 2020
- Cash burn rate steady
- Cash and Cash Equivalents of $15.4 million as of June 30, 2020, which is expected to support operations through 2021
Headline financials
Revenue & EPS history
Celcuity · Revenue · Quarterly
$0
Forward guidance
Celcuity anticipates completing the development of a CELsignia RAS test for breast cancer patients by the end of 2020 and expects interim results from the FACT-1 and FACT-2 trials in the second half of 2021.
Tailwinds
- Expect to complete development of a CELsignia RAS test for breast cancer patients by the end of 2020.
- Interim results from the FACT-1 and FACT-2 trials are expected in the second half of 2021
- Expect to announce new clinical trial collaborations with pharmaceutical companies and trial sponsors by the end of 2020
- Multiple clinical trial collaborations amongst several major pharmaceutical companies advancing towards close this year.
- Data for two new CELsignia tests in two different tumor types announced during past nine months.
Headwinds
- FACT-1 and FACT-2 trials remain somewhat impacted by COVID-19 related delays
- Total operating expenses were $2.21 million for the second quarter of 2020, compared to $1.84 million for the second quarter of 2019.
- Net loss for the second quarter of 2020 was $2.20 million, or $0.21 per share, compared to a net loss of $1.72 million, or $0.17 per share, for the second quarter of 2019.
- Net cash used in operating activities for the second quarter of 2020 was $1.56 million, compared to $1.23 million for the second quarter of 2019.
- COVID-19 presents headwinds for collaboration discussions.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
-0.9%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+1.8%
Avg return
30 days after
38%
13 / 34 earnings
Positive
+23.3%
Q4 2023
Best reaction
-13.5%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +5.5% | -4.7% | -32.5% | |
| Q3 2025 | +1.1% | +7.6% | +23.6% | |
| Q2 2025 | +0.1% | -6.0% | +5.8% | |
| Q1 2025 | -2.6% | -1.9% | +11.5% | |
| Q4 2024 | -8.1% | -14.4% | +6.8% | |
| Q3 2024 | -13.5% | -14.8% | -14.5% | |
| Q2 2024 | -6.2% | +3.0% | -10.9% | |
| Q1 2024 | +4.6% | -0.5% | -11.0% | |
| Q4 2023 | +23.3% | +18.6% | -9.1% | |
| Q3 2023 | +11.3% | +18.7% | +37.4% | |
| Q2 2023 | -1.0% | -1.2% | -8.7% | |
| Q1 2023 | +2.2% | +4.7% | +9.5% | |
| Q4 2022 | -5.0% | +3.7% | -3.2% | |
| Q3 2022 | +3.0% | -0.5% | -6.7% | |
| Q2 2022 | -1.0% | -4.3% | -14.2% | |
| Q1 2022 | +2.8% | +6.5% | +57.6% | |
| Q4 2021 | -2.8% | +0.0% | -16.8% | |
| Q3 2021 | -5.9% | -7.7% | -26.6% | |
| Q2 2021 | -1.3% | +2.3% | +5.1% | |
| Q1 2021 | -4.5% | -0.8% | -0.8% | |
| Q4 2020 | +1.1% | +7.4% | -3.9% | |
| Q3 2020 | +0.5% | +64.0% | +93.3% | |
| Q2 2020 | -0.2% | -6.9% | -11.3% | |
| Q1 2020 | -2.4% | -13.8% | +90.3% | |
| Q4 2019 | -4.8% | -3.7% | -23.5% | |
| Q3 2019 | +1.4% | +1.0% | -23.1% | |
| Q2 2019 | +0.7% | -0.4% | -14.9% | |
| Q1 2019 | -2.5% | +0.2% | -6.8% | |
| Q4 2018 | -4.7% | -8.5% | -12.8% | |
| Q3 2018 | -7.2% | -6.2% | -17.8% | |
| Q2 2018 | -1.1% | +2.8% | -15.0% | |
| Q1 2018 | -4.0% | -2.4% | -2.2% | |
| Q4 2017 | -2.4% | -9.9% | +18.6% | |
| Q3 2017 | -5.6% | -15.7% | -13.2% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro